Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

Chronic isolation stress is associated with increased colonic and motor symptoms in the A53T mouse model of Parkinson's disease.

Diwakarla S, Finkelstein DI, Constable R, Artaiz O, Di Natale M, McQuade RM, Lei E, Chai XY, Ringuet MT, Fothergill LJ, Lawson VA, Ellett LJ, Berger JP, Furness JB.

Neurogastroenterol Motil. 2020 Mar;32(3):e13755. doi: 10.1111/nmo.13755. Epub 2019 Nov 10.

PMID:
31709672
2.

Test of the Einstein Equivalence Principle near the Galactic Center Supermassive Black Hole.

Amorim A, Bauböck M, Berger JP, Brandner W, Clénet Y, Coudé du Foresto V, de Zeeuw PT, Dexter J, Duvert G, Ebert M, Eckart A, Eisenhauer F, Förster Schreiber NM, Garcia P, Gao F, Gendron E, Genzel R, Gillessen S, Habibi M, Haubois X, Henning T, Hippler S, Horrobin M, Hubert Z, Jiménez Rosales A, Jocou L, Kervella P, Lacour S, Lapeyrère V, Le Bouquin JB, Léna P, Ott T, Paumard T, Perraut K, Perrin G, Pfuhl O, Rabien S, Rodríguez-Coira G, Rousset G, Scheithauer S, Sternberg A, Straub O, Straubmeier C, Sturm E, Tacconi LJ, Vincent F, von Fellenberg S, Waisberg I, Widmann F, Wieprecht E, Wiezorrek E, Yazici S; GRAVITY Collaboration.

Phys Rev Lett. 2019 Mar 15;122(10):101102. doi: 10.1103/PhysRevLett.122.101102.

PMID:
30932663
3.

Endothelial Cell-Targeted Deletion of PPARγ Blocks Rosiglitazone-Induced Plasma Volume Expansion and Vascular Remodeling in Adipose Tissue.

Akiyama TE, Skelhorne-Gross GE, Lightbody ED, Rubino RE, Shi JY, McNamara LA, Sharma N, Zycband EI, Gonzalez FJ, Liu H, Woods JW, Chang CH, Berger JP, Nicol CJB.

J Pharmacol Exp Ther. 2019 Mar;368(3):514-523. doi: 10.1124/jpet.118.250985. Epub 2019 Jan 3.

PMID:
30606762
4.

Limited Added Value of Magnetic Resonance Imaging After Dynamic Transvaginal Ultrasound for Preoperative Staging of Endometriosis in Daily Practice: A Prospective Cohort Study.

Berger JP, Rhemrev J, Smeets M, Henneman O, English J, Jansen FW.

J Ultrasound Med. 2019 Apr;38(4):989-996. doi: 10.1002/jum.14783. Epub 2018 Sep 23.

PMID:
30244483
5.

Surgical outcomes of laparoscopic hysterectomy with concomitant endometriosis without bowel or bladder dissection: a cohort analysis to define a case-mix variable.

Sandberg EM, Driessen SRC, Bak EAT, van Geloven N, Berger JP, Smeets MJGH, Rhemrev JPT, Jansen FW.

Gynecol Surg. 2018;15(1):8. doi: 10.1186/s10397-018-1039-3. Epub 2018 Mar 16.

6.

Large granulation cells on the surface of the giant star π1 Gruis.

Paladini C, Baron F, Jorissen A, Le Bouquin JB, Freytag B, Van Eck S, Wittkowski M, Hron J, Chiavassa A, Berger JP, Siopis C, Mayer A, Sadowski G, Kravchenko K, Shetye S, Kerschbaum F, Kluska J, Ramstedt S.

Nature. 2018 Jan 18;553(7688):310-312. doi: 10.1038/nature25001. Epub 2017 Dec 20.

PMID:
29258298
7.

A comparative study of the binding properties, dipeptidyl peptidase-4 (DPP-4) inhibitory activity and glucose-lowering efficacy of the DPP-4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice.

Berger JP, SinhaRoy R, Pocai A, Kelly TM, Scapin G, Gao YD, Pryor KAD, Wu JK, Eiermann GJ, Xu SS, Zhang X, Tatosian DA, Weber AE, Thornberry NA, Carr RD.

Endocrinol Diabetes Metab. 2017 Nov 24;1(1):e00002. doi: 10.1002/edm2.2. eCollection 2018 Jan.

8.

Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus.

Xu J, Lin S, Myers RW, Trujillo ME, Pachanski MJ, Malkani S, Chen HS, Chen Z, Campbell B, Eiermann GJ, Elowe N, Farrer BT, Feng W, Fu Q, Kats-Kagan R, Kavana M, McMasters DR, Mitra K, Tong X, Xu L, Zhang F, Zhang R, Addona GH, Berger JP, Zhang B, Parmee ER.

Bioorg Med Chem Lett. 2017 May 1;27(9):2063-2068. doi: 10.1016/j.bmcl.2016.10.088. Epub 2016 Oct 31.

PMID:
28284809
9.

Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus.

Xu J, Lin S, Myers RW, Addona G, Berger JP, Campbell B, Chen HS, Chen Z, Eiermann GJ, Elowe NH, Farrer BT, Feng W, Fu Q, Kats-Kagan R, Kavana M, Malkani S, McMasters DR, Mitra K, Pachanski MJ, Tong X, Trujillo ME, Xu L, Zhang B, Zhang F, Zhang R, Parmee ER.

Bioorg Med Chem Lett. 2017 May 1;27(9):2069-2073. doi: 10.1016/j.bmcl.2016.10.085. Epub 2016 Oct 31.

PMID:
28284804
10.

Spontaneous haemoperitoneum in pregnancy and endometriosis: a case series.

Lier M, Malik RF, van Waesberghe J, Maas JW, van Rumpt-van de Geest DA, Coppus SF, Berger JP, van Rijn BB, Janssen PF, de Boer MA, de Vries J, Jansen FW, Brosens IA, Lambalk CB, Mijatovic V.

BJOG. 2017 Jan;124(2):306-312. doi: 10.1111/1471-0528.14371. Epub 2016 Oct 5.

11.
12.

[History of cancer and chemotherapy before chemotherapy].

Bonnichon P, Berger JP, Bonni N, Fontaine M, Pion-Graff J.

Hist Sci Med. 2014 Oct-Dec;48(4):469-74. French.

PMID:
25962214
13.

Hypoxia: an unusual cause with specific treatment.

Berger JP, Raveendran G, Ingbar DH, Bhargava M.

Case Rep Pulmonol. 2015;2015:956341. doi: 10.1155/2015/956341. Epub 2015 Feb 4.

14.

Malondialdehyde-acetaldehyde (MAA) adducted proteins bind to scavenger receptor A in airway epithelial cells.

Berger JP, Simet SM, DeVasure JM, Boten JA, Sweeter JM, Kharbanda KK, Sisson JH, Wyatt TA.

Alcohol. 2014 Aug;48(5):493-500. doi: 10.1016/j.alcohol.2014.02.005. Epub 2014 May 11.

15.

Downstream signaling pathways in mouse adipose tissues following acute in vivo administration of fibroblast growth factor 21.

Muise ES, Souza S, Chi A, Tan Y, Zhao X, Liu F, Dallas-Yang Q, Wu M, Sarr T, Zhu L, Guo H, Li Z, Li W, Hu W, Jiang G, Paweletz CP, Hendrickson RC, Thompson JR, Mu J, Berger JP, Mehmet H.

PLoS One. 2013 Sep 6;8(9):e73011. doi: 10.1371/journal.pone.0073011. eCollection 2013.

16.

Pegylated Fgf21 rapidly normalizes insulin-stimulated glucose utilization in diet-induced insulin resistant mice.

Camacho RC, Zafian PT, Achanfuo-Yeboah J, Manibusan A, Berger JP.

Eur J Pharmacol. 2013 Sep 5;715(1-3):41-5. doi: 10.1016/j.ejphar.2013.06.023. Epub 2013 Jul 3.

PMID:
23831019
17.

FGF21 suppresses hepatic glucose production through the activation of atypical protein kinase Cι/λ.

Kong LJ, Feng W, Wright M, Chen Y, Dallas-yang Q, Zhou YP, Berger JP.

Eur J Pharmacol. 2013 Feb 28;702(1-3):302-8. doi: 10.1016/j.ejphar.2012.11.065. Epub 2013 Jan 7.

PMID:
23305840
18.

A genome-wide siRNA screen to identify modulators of insulin sensitivity and gluconeogenesis.

Yang R, Lacson RG, Castriota G, Zhang XD, Liu Y, Zhao W, Einstein M, Camargo LM, Qureshi S, Wong KK, Zhang BB, Ferrer M, Berger JP.

PLoS One. 2012;7(5):e36384. doi: 10.1371/journal.pone.0036384. Epub 2012 May 9.

19.

Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor γ (PPARγ) modulators display attenuated and selective gene regulatory activity in comparison with PPARγ full agonists.

Tan Y, Muise ES, Dai H, Raubertas R, Wong KK, Thompson GM, Wood HB, Meinke PT, Lum PY, Thompson JR, Berger JP.

Mol Pharmacol. 2012 Jul;82(1):68-79. doi: 10.1124/mol.111.076679. Epub 2012 Apr 10.

PMID:
22496518
21.

FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents.

Mu J, Pinkstaff J, Li Z, Skidmore L, Li N, Myler H, Dallas-Yang Q, Putnam AM, Yao J, Bussell S, Wu M, Norman TC, Rodriguez CG, Kimmel B, Metzger JM, Manibusan A, Lee D, Zaller DM, Zhang BB, DiMarchi RD, Berger JP, Axelrod DW.

Diabetes. 2012 Feb;61(2):505-12. doi: 10.2337/db11-0838. Epub 2011 Dec 30.

22.

Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.

Liu W, Lau F, Liu K, Wood HB, Zhou G, Chen Y, Li Y, Akiyama TE, Castriota G, Einstein M, Wang C, McCann ME, Doebber TW, Wu M, Chang CH, McNamara L, McKeever B, Mosley RT, Berger JP, Meinke PT.

J Med Chem. 2011 Dec 22;54(24):8541-54. doi: 10.1021/jm201061j. Epub 2011 Nov 28.

PMID:
22070604
23.

Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs.

Eiki J, Nagata Y, Futamura M, Sasaki-Yamamoto K, Iino T, Nishimura T, Chiba M, Ohyama S, Yoshida-Yoshimioto R, Fujii K, Hosaka H, Goto-Shimazaki H, Kadotani A, Ohe T, Lin S, Langdon RB, Berger JP.

Mol Pharmacol. 2011 Dec;80(6):1156-65. doi: 10.1124/mol.111.074401. Epub 2011 Sep 21.

PMID:
21937665
24.

cSSMD: assessing collective activity for addressing off-target effects in genome-scale RNA interference screens.

Zhang XD, Santini F, Lacson R, Marine SD, Wu Q, Benetti L, Yang R, McCampbell A, Berger JP, Toolan DM, Stec EM, Holder DJ, Soper KA, Heyse JF, Ferrer M.

Bioinformatics. 2011 Oct 15;27(20):2775-81. doi: 10.1093/bioinformatics/btr474. Epub 2011 Aug 16.

25.

The use of SSMD-based false discovery and false nondiscovery rates in genome-scale RNAi screens.

Zhang XD, Lacson R, Yang R, Marine SD, McCampbell A, Toolan DM, Hare TR, Kajdas J, Berger JP, Holder DJ, Heyse JF, Ferrer M.

J Biomol Screen. 2010 Oct;15(9):1123-31. doi: 10.1177/1087057110381919. Epub 2010 Sep 17.

PMID:
20852024
26.

Design and synthesis of a new class of malonyl-CoA decarboxylase inhibitors with anti-obesity and anti-diabetic activities.

Tang H, Yan Y, Feng Z, de Jesus RK, Yang L, Levorse DA, Owens KA, Akiyama TE, Bergeron R, Castriota GA, Doebber TW, Ellsworth KP, Lassman ME, Li C, Wu MS, Zhang BB, Chapman KT, Mills SG, Berger JP, Pasternak A.

Bioorg Med Chem Lett. 2010 Oct 15;20(20):6088-92. doi: 10.1016/j.bmcl.2010.08.047. Epub 2010 Aug 20.

PMID:
20832306
27.

RNAi-mediated germline knockdown of FABP4 increases body weight but does not improve the deranged nutrient metabolism of diet-induced obese mice.

Yang R, Castriota G, Chen Y, Cleary MA, Ellsworth K, Shin MK, Tran JL, Vogt TF, Wu M, Xu S, Yang X, Zhang BB, Berger JP, Qureshi SA.

Int J Obes (Lond). 2011 Feb;35(2):217-25. doi: 10.1038/ijo.2010.128. Epub 2010 Jul 6.

28.

An infrared integrated optic astronomical beam combiner for stellar interferometry at 3-4 microm.

Hsiao HK, Winick KA, Monnier JD, Berger JP.

Opt Express. 2009 Oct 12;17(21):18489-500. doi: 10.1364/OE.17.018489.

PMID:
20372579
29.

Preliminary report: pharmacologic 11beta-hydroxysteroid dehydrogenase type 1 inhibition increases hepatic fat oxidation in vivo and expression of related genes in rats fed an obesogenic diet.

Berthiaume M, Laplante M, Festuccia WT, Berger JP, Thieringer R, Deshaies Y.

Metabolism. 2010 Jan;59(1):114-7. doi: 10.1016/j.metabol.2009.07.015. Epub 2009 Sep 18.

PMID:
19766266
30.

Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree of unsaturation.

Gorczynski MJ, Smitherman PK, Akiyama TE, Wood HB, Berger JP, King SB, Morrow CS.

J Med Chem. 2009 Aug 13;52(15):4631-9. doi: 10.1021/jm900326c.

31.

A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors.

Shen HC, Ding FX, Deng Q, Xu S, Tong X, Zhang X, Chen Y, Zhou G, Pai LY, Alonso-Galicia M, Roy S, Zhang B, Tata JR, Berger JP, Colletti SL.

Bioorg Med Chem Lett. 2009 Oct 1;19(19):5716-21. doi: 10.1016/j.bmcl.2009.08.006. Epub 2009 Aug 7.

PMID:
19700315
32.

Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.

Shen HC, Ding FX, Deng Q, Xu S, Chen HS, Tong X, Tong V, Zhang X, Chen Y, Zhou G, Pai LY, Alonso-Galicia M, Zhang B, Roy S, Tata JR, Berger JP, Colletti SL.

Bioorg Med Chem Lett. 2009 Sep 15;19(18):5314-20. doi: 10.1016/j.bmcl.2009.07.138. Epub 2009 Aug 6.

PMID:
19682899
33.

Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.

Shen HC, Ding FX, Wang S, Deng Q, Zhang X, Chen Y, Zhou G, Xu S, Chen HS, Tong X, Tong V, Mitra K, Kumar S, Tsai C, Stevenson AS, Pai LY, Alonso-Galicia M, Chen X, Soisson SM, Roy S, Zhang B, Tata JR, Berger JP, Colletti SL.

J Med Chem. 2009 Aug 27;52(16):5009-12. doi: 10.1021/jm900725r.

PMID:
19645482
34.

Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.

Liu W, Liu K, Wood HB, McCann ME, Doebber TW, Chang CH, Akiyama TE, Einstein M, Berger JP, Meinke PT.

J Med Chem. 2009 Jul 23;52(14):4443-53. doi: 10.1021/jm900367w.

PMID:
19530681
35.

Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma and extracellular fluid volume.

Acton JJ 3rd, Akiyama TE, Chang CH, Colwell L, Debenham S, Doebber T, Einstein M, Liu K, McCann ME, Moller DE, Muise ES, Tan Y, Thompson JR, Wong KK, Wu M, Xu L, Meinke PT, Berger JP, Wood HB.

J Med Chem. 2009 Jul 9;52(13):3846-54. doi: 10.1021/jm900097m. Erratum in: J Med Chem. 2013 Nov 27;56(22):9368. Tan, Yugen [corrected to Tan, Yejun].

PMID:
19507861
36.

Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors.

Shen HC, Ding FX, Wang S, Xu S, Chen HS, Tong X, Tong V, Mitra K, Kumar S, Zhang X, Chen Y, Zhou G, Pai LY, Alonso-Galicia M, Chen X, Zhang B, Tata JR, Berger JP, Colletti SL.

Bioorg Med Chem Lett. 2009 Jul 1;19(13):3398-404. doi: 10.1016/j.bmcl.2009.05.036. Epub 2009 May 18.

PMID:
19481932
37.

Proangiogenic contribution of adiponectin toward mammary tumor growth in vivo.

Landskroner-Eiger S, Qian B, Muise ES, Nawrocki AR, Berger JP, Fine EJ, Koba W, Deng Y, Pollard JW, Scherer PE.

Clin Cancer Res. 2009 May 15;15(10):3265-76. doi: 10.1158/1078-0432.CCR-08-2649. Epub 2009 May 15.

38.

Evidence that inhibition of insulin receptor signaling activity by PC-1/ENPP1 is dependent on its enzyme activity.

Chin CN, Dallas-Yang Q, Liu F, Ho T, Ellsworth K, Fischer P, Natasha T, Ireland C, Lu P, Li C, Wang IM, Strohl W, Berger JP, An Z, Zhang BB, Jiang G.

Eur J Pharmacol. 2009 Mar 15;606(1-3):17-24. doi: 10.1016/j.ejphar.2009.01.016. Epub 2009 Jan 22.

PMID:
19374858
39.

Additive action of 11beta-HSD1 inhibition and PPAR-gamma agonism on hepatic steatosis and triglyceridemia in diet-induced obese rats.

Berthiaume M, Laplante M, Festuccia WT, Berger JP, Thieringer R, Deshaies Y.

Int J Obes (Lond). 2009 May;33(5):601-4. doi: 10.1038/ijo.2009.33. Epub 2009 Feb 17.

PMID:
19223847
40.

[A woman with an obstetric curiosity].

Berger JP, Van Den Bosch T.

Ned Tijdschr Geneeskd. 2010;154:A335. Dutch.

PMID:
20356433
41.

Differential potencies of naturally occurring regioisomers of nitrolinoleic acid in PPARgamma activation.

Alexander RL, Wright MW, Gorczynski MJ, Smitherman PK, Akiyama TE, Wood HB, Berger JP, King SB, Morrow CS.

Biochemistry. 2009 Jan 20;48(2):492-8. doi: 10.1021/bi8016747.

PMID:
19105608
42.

Development of a novel GLUT4 translocation assay for identifying potential novel therapeutic targets for insulin sensitization.

Liu F, Dallas-Yang Q, Castriota G, Fischer P, Santini F, Ferrer M, Li J, Akiyama TE, Berger JP, Zhang BB, Jiang G.

Biochem J. 2009 Mar 1;418(2):413-20. doi: 10.1042/BJ20082051.

PMID:
19035854
43.

Tissue-specific postprandial clearance is the major determinant of PPARgamma-induced triglyceride lowering in the rat.

Laplante M, Festuccia WT, Soucy G, Blanchard PG, Renaud A, Berger JP, Olivecrona G, Deshaies Y.

Am J Physiol Regul Integr Comp Physiol. 2009 Jan;296(1):R57-66. doi: 10.1152/ajpregu.90552.2008. Epub 2008 Oct 29.

44.

Highly functionalized 7-azaindoles as selective PPAR gamma modulators.

Debenham SD, Chan A, Lau FW, Liu W, Wood HB, Lemme K, Colwell L, Habulihaz B, Akiyama TE, Einstein M, Doebber TW, Sharma N, Wang CF, Wu M, Berger JP, Meinke PT.

Bioorg Med Chem Lett. 2008 Sep 1;18(17):4798-801. doi: 10.1016/j.bmcl.2008.07.103. Epub 2008 Jul 30.

PMID:
18701276
45.

Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice.

Tan CP, Feng Y, Zhou YP, Eiermann GJ, Petrov A, Zhou C, Lin S, Salituro G, Meinke P, Mosley R, Akiyama TE, Einstein M, Kumar S, Berger JP, Mills SG, Thornberry NA, Yang L, Howard AD.

Diabetes. 2008 Aug;57(8):2211-9. doi: 10.2337/db08-0130. Epub 2008 May 13.

46.

Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states.

Muise ES, Azzolina B, Kuo DW, El-Sherbeini M, Tan Y, Yuan X, Mu J, Thompson JR, Berger JP, Wong KK.

Mol Pharmacol. 2008 Aug;74(2):403-12. doi: 10.1124/mol.108.044826. Epub 2008 May 8.

PMID:
18467542
47.

A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.

Chang CH, McNamara LA, Wu MS, Muise ES, Tan Y, Wood HB, Meinke PT, Thompson JR, Doebber TW, Berger JP, McCann ME.

Eur J Pharmacol. 2008 Apr 14;584(1):192-201. doi: 10.1016/j.ejphar.2007.12.036. Epub 2008 Feb 14.

PMID:
18346728
48.

Integrated Optics for Astronomical Interferometry. III. Optical Validation of a Planar Optics Two-Telescope Beam Combiner.

Haguenauer P, Berger JP, Rousselet-Perraut K, Kern P, Malbet F, Schanen-Duport I, Benech P.

Appl Opt. 2000 May 1;39(13):2130-9.

PMID:
18345117
49.

Malonyl CoenzymeA decarboxylase regulates lipid and glucose metabolism in human skeletal muscle.

Bouzakri K, Austin R, Rune A, Lassman ME, Garcia-Roves PM, Berger JP, Krook A, Chibalin AV, Zhang BB, Zierath JR.

Diabetes. 2008 Jun;57(6):1508-16. doi: 10.2337/db07-0583. Epub 2008 Feb 26.

50.

The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities.

Einstein M, Akiyama TE, Castriota GA, Wang CF, McKeever B, Mosley RT, Becker JW, Moller DE, Meinke PT, Wood HB, Berger JP.

Mol Pharmacol. 2008 Jan;73(1):62-74. Epub 2007 Oct 16.

PMID:
17940191

Supplemental Content

Loading ...
Support Center